Fesoterodine
Drugs For Urinary Frequency and Incontinence
Sold as Toviaz
- Drug class
- Drugs For Urinary Frequency and Incontinence
- Availability
- See label
- Markets covered
- 2
- Products on record
- 29
Overview
Fesoterodine is an active pharmaceutical ingredient in the Drugs For Urinary Frequency and Incontinence group (G04BD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 28 | May 15, 2026 |
| EU European Union | EMA | 1 | March 4, 2025 |
GBUnited Kingdom· MHRA
28 products
Uses
Fesoterodine fumarate is indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.
How to take
EUEuropean Union· EMA
1 product
Uses
TOVIAZ is indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.
How to take
Drug interactions
Known interactions involving Fesoterodine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 265. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL068310327 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/000723 · revised March 4, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.